Further development is ongoing in both solid tumors and hematological malignancies with different molecules (MDX-1106 or nivolumab, and CT-011 or pidilizumab as anti-PD-1; MDX-1105 as anti-PD-L1, and other molecules directed against T-cell Immunoglobulin and mucin domain-containing protein 3 [Tim-3], lymphocyte activation gene-3 [LAG-3], and V-domain Ig-containing suppressor of T-cell activation [VISTA]). Here, LAG3 is linked to hematologic disorder.